Skip to main content Skip to footer
Nighthawk Biosciences, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Biothreat Advisory Board
  • Ecosystem
    • Overview
    • Subsidiaries
  • Products
    • Anthim
    • Publications
  • Investors & News
    • Overview
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
    • Corporate Presentation
  • Careers
  • Contact

Press Releases

Investors & News

Investors & News

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Corporate Presentation
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jul 29, 2020 7:30am EDT

Heat Biologics COVID-19 Vaccine Demonstrates Immunogenicity Proof-of-Concept in Pre-Clinical Studies

Jul 27, 2020 6:30am EDT

Heat Biologics Regains Compliance with Nasdaq Minimum Bid Price Rule

Jun 22, 2020 7:30am EDT

Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35

Jun 18, 2020 7:30am EDT

Heat Biologics Announces Initiation of the Lead Clinical Trial Site for PTX-35

Jun 08, 2020 7:30am EDT

Heat Biologics Announces FDA Clearance of Investigational New Drug (IND) Application for PTX-35

Jun 04, 2020 7:30am EDT

Heat Biologics Provides Update on COVID-19 Vaccine Efforts

May 29, 2020 8:00am EDT

Heat Biologics Presents Positive Survival Benefit for HS-110 in Combination with Nivolumab in Phase 2 Lung Cancer Trial at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

May 27, 2020 8:00am EDT

Heat Biologics Announces Collaboration with Waisman Biomanufacturing to Manufacture COVID-19 Vaccine

May 15, 2020 9:30am EDT

Heat Biologics Provides First Quarter 2020 Business Update

May 14, 2020 8:00am EDT

Positive Survival Data from Phase 2 Lung Cancer Trial Accepted for Presentation at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • …
  • Page 29
  • Next Pagearrow_forward
rss_feed News RSS
NightHawk Biosciences

OUR ECOSYSTEM

SkunkWorx Bio
Elusys Therapeutics Inc.
Scorpius Biological Services
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 Nighthawk Biosciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap
  • Visit us on LinkedIn
  • Visit us on Twitter
  • Visit us on YouTube
  • Visit us on Facebook

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.